Sar­to­rius to ac­quire French man­u­fac­tur­er for $2.6B+ in cell and gene ther­a­py play

The Ger­man life sci­ence group Sar­to­rius will be pick­ing up French con­tract man­u­fac­tur­er Poly­plus for the price of €2.4 bil­lion, or $2.6 bil­lion.

On Fri­day, Sar­to­rius an­nounced the ac­qui­si­tion through its French sub­group, Sar­to­rius Ste­d­im Biotech, which will be ac­quir­ing Poly­plus from pri­vate in­vestors Archimed and WP GG Hold­ings IV. Poly­plus has 270 em­ploy­ees and pro­duces ma­te­ri­als and com­po­nents that go in­to mak­ing vi­ral vec­tors that are used in cell and gene ther­a­pies. This in­cludes DNA/RNA reagents as well as plas­mid DNA. Poly­plus has lo­ca­tions in France, Bel­gium, Chi­na and the US.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER